We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Use of Premature Paragraph IV Notices Pushes FDA to Take Action
Use of Premature Paragraph IV Notices Pushes FDA to Take Action
FDA plans to crack down on generic drugmakers initiating patent litigation early by sending premature Paragraph IV certification notices to innovators, though it’s not yet clear what actions the agency intends to take.